Non-Profits
Filter News
Found 4,504 articles
-
The Foundation for Sarcoidosis Research (FSR) to provide $50,000 in Sarcoidosis Research Funding Exploring Environmental Causes of sarcoidosis and for Identifying Neurosarc Biomarkers
11/23/2022
The Foundation for Sarcoidosis Research is pleased to announce the funding for two new pilot projects in sarcoidosis.
-
New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results
11/21/2022
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) and HealthTree Foundation today announced findings from a new survey of 635 U.S. multiple myeloma patients which revealed important insights about the value of minimal residual disease (MRD) testing from the patient’s perspective.
-
Dr. Elizabeth Cherot Joins March of Dimes as Sr. Vice President, Chief Medical & Health Officer
11/17/2022
March of Dimes, the nation's leading nonprofit fighting for the health of all moms and babies, announced the appointment of Dr. Elizabeth Cherot, as Senior Vice President and Chief Medical and Health Officer effective January 9, 2023.
-
CurePSP Expands Specialized Care Network for Rare Neurodegenerative Diseases
11/17/2022
CurePSP has announced the designation of Queen's Parkinson's and Movement Disorders Center in Hawaii and the Department of Neurology at the University of Michigan as CurePSP Centers of Care, bringing the total to 30 centers across the United States and Canada.
-
FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Eight Years
11/14/2022
Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, announced today that the U.S. Food and Drug Administration (FDA) has approved Medicines360's Supplemental New Drug Application (sNDA) to extend the duration of use of Liletta® (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to eight years.
-
Lupus Foundation of America Recognizes Scientists for Exceptional Contributions in Lupus Research
11/13/2022
The Lupus Foundation of America is pleased to honor two leading scientists for their notable contributions to lupus research at the 2022 Evelyn V. Hess Reception held during the American College of Rheumatology convergence 2022 meeting this evening in Philadelphia, PA.
-
National Kidney Foundation Appoints Dr. Kirk Campbell of Mount Sinai as President Elect of the National Board
11/11/2022
The National Kidney Foundation is pleased to announce that Dr. Kirk Campbell, the Irene and Dr. Arthur M. Fishberg Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Vice Chair of the Department of Medicine for Diversity, Equity, and Inclusion, has begun his two-year term as President Elect of NKF's National Board of Directors.
-
Cold Spring Harbor Laboratory receives new funding for free biomedical research platforms
11/8/2022
Cold Spring Harbor Laboratory announced that preprint servers bioRxiv and medRxiv have received renewed funding from the Chan Zuckerberg Initiative.
-
The only patient in an FDA-sanctioned clinical trial assessing a CRISPR-based therapy for a rare form of Duchenne muscular dystrophy has died, according to study sponsor Cure Rare Disease.
-
National Kidney Foundation Appoints Prominent Marketing Expert to Board of Directors
11/4/2022
The National Kidney Foundation is proud to announce the appointment of Lynn Pina, Chief Marketing Officer of GeoBlue, to its National Board of Directors.
-
National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels
11/4/2022
Ardelyx, Inc. in partnership with the National Kidney Foundation, announced results from a survey of patients with chronic kidney disease on dialysis conducted to better understand patients' experience managing serum phosphorus levels.
-
Health care providers to Canadian governments: this is our prescription for hope
11/4/2022
Canada's health ministers have a golden opportunity next week to bring hope to Canadians and to 1.3 million health care workers from coast to coast to coast by charting a clear path of tangible action to help stabilize and begin rebuilding our struggling health systems.
-
American Liver Foundation Hosts the 31st Annual Irwin M. Arias Symposium
11/3/2022
The American Liver Foundation is pleased to host its 31st annual Irwin M. Arias Symposium, Bridging Basic Science and Liver Disease, on November 10th from 9AM to 5PM ET.
-
The Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature
11/2/2022
The Access to Advanced Health Institute announced results from a study of their new RNA vaccine against COVID-19.
-
The Michael J. Fox Foundation for Parkinson's Research Honors J. Timothy Greenamyre, MD, PhD, with Robert A. Pritzker Prize for Leadership in Parkinson's Research
11/1/2022
The Michael J. Fox Foundation for Parkinson's Research has awarded the 2022 Robert A. Pritzker Prize for Leadership in Parkinson's Research to J. Timothy Greenamyre, MD, PhD, Professor and Vice-Chair of Neurology and Director of the Pittsburgh Institute for Neurodegenerative Diseases at the University of Pittsburgh.
-
Lung Cancer Research Foundation Welcomes Chief Scientific Officer
11/1/2022
The Lung Cancer Research Foundation is pleased to announce the addition of Antoinette J. Wozniak, MD, FACP, FASCO to its senior leadership team as its first Chief Scientific Officer.
-
First Round of Late-Breaking Clinical Trial Results Announced at VIVA22
11/1/2022
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of three Late-Breaking Clinical Trials session at the VIVA22 conference, hosted at Wynn Las Vegas.
-
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA22
11/1/2022
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of three Late-Breaking Clinical Trials sessions at the VIVA22 conference, hosted at Wynn Las Vegas.
-
The Leukemia & Lymphoma Society and Wawa and The Wawa Foundation Join Forces to End Blood Cancer
10/31/2022
The North Florida Region of The Leukemia & Lymphoma Society and Wawa and The Wawa Foundation have joined forces to end blood cancer, a disease diagnosed every 180 seconds in the U.S.
-
First-Ever Late-Breaking Clinical Trial Results Announced at The VEINS 2022
10/31/2022
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first Late-Breaking Clinical Trials session at The VEINS conference, hosted at Wynn Las Vegas.